A Phase 1/2 interventional study of EO4010 in Colorectal Cancer Metastatic, sponsored by Enterome. Terminated at 6 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Enterome · Phase 1/2, Interventional, and Treatment
How we know · 4 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.
Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 408th largest by enrollment of the 464 interventional ones that give a count, is one of 26 that started in 2023, is one of 55 in phase 1/2, and was the 464th registered.
6,555 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.
Browse Colorectal Neoplasms studies →111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:
Centre Hospitalier Intercommunal Creteil · Sites in France
Ages 18+
Centre Antoine Lacassagne · Sites in France
Ages 18–75
Verastem, Inc. · Sites in France, United States, Australia and 2 more countries
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+ · Healthy volunteers
EMD Serono Research & Development Institute, Inc. · Sites in France, United States, Argentina and 16 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
583 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 116 · Phase 2 207 · Phase 3 97 · Phase 4 6
First in 1993; this study’s year is marked. 26 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 25 is below the median of 76 across 4,811 interventional studies indexed under Colorectal Neoplasms.
Median enrollment 152 across the 464 interventional studies, 274 across the 103 observational. Of the 358 that completed or were terminated, 107 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
224 of 583 have an industry lead sponsor. The 10 most frequent:
Enterome is the lead sponsor of 8 studies on the registry; none are open to participants now.
Enterome has 2 studies filed under Colorectal Neoplasms — fewer than ten, so there is no comparison to draw.
38 of the studies in Colorectal Neoplasms with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07520578Phase 3University Hospital, CaenEFFECTIVENESS OF EARLY INFORMATION AND ENDORSMENT BY GP TO INCREASE COLONOSCOPY FOLLOW-UP AND REDUCE DELAYS IN PEOPLE WITH A POSITIVE COLORECTAL CANCER SCREENING TEST. (SUIVICOLO) | 2027-03-24 |
| NCT07116668SafeHeal IncSafeHeal Colovac Anastomosis Protection Device Evaluation Pivotal Study | 2026-12 |
| NCT07151040One-carbon Therapeutics ABPhase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors | 2026-12 |
| NCT04585750PMV Pharmaceuticals, IncThe Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | 2026-12-15 |
| NCT05706779Federation Francophone de Cancerologie DigestiveEncorafenib Plus Cetuximab in a Neoadjuvant Setting in Patients With BRAF Mutation Localised Colon or Upper Rectum Cancer | 2026-12-30 |
Add all 38 to your calendar (.ics) → With an account.
Among the 583 studies in Colorectal Neoplasms with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open-label multicenter study
This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab and/or bevacizumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with the following abnormal laboratory values:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
E04010 Monotherapy
Drug: EO4010
E04010 in combination with nivolumab
Drug: EO4010
E04010 in combination with nivolumab and/or bevacizumab
Drug: EO4010
Sequential assignment
Also known as: Nivolumab, Bevacizumab
This study also gives NivolumabStudies of NivolumabNivolumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab
Incidences of treatment-emergent Serious Adverse Events (SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
Time frame: 24 months
Percentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides)
Immunogenicity response of EO4010 (all peptides) for the three tests together: IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]. A patient is defined as positive if the result of one of the three tests (IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]) shows a positive response
Time frame: Week 5 after first dose of EO4010
Overall Response Rate
Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
Time frame: 24 months
Disease Control Rate
Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria
Time frame: 24 months
Time to Response
Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
Time frame: 24 months
Duration of Response
Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria
Time frame: 24 months
Progression Free Survival
Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria
Time frame: 24 months
Overall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up
Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up
Time frame: 24 months
| Milestone | Cohort 1a | Cohort 2 | Cohort 3a | Cohorts 1b-1c-1d |
|---|---|---|---|---|
| Started | 3 | 17 | 5 | 0 |
| Completed | 3 | 17 | 5 | 0 |
| Not completed | 0 | 0 | 0 | 0 |
Incidences of treatment-emergent Serious Adverse Events (SAEs) using the National Cancer Institute-Common Terminology Criteria for AEs (NCI-CTCAE) v5.0.
| Participants | Overall (All Cohorts) | Cohort 1a (Overall) | Cohort 1a (Monotherapy) | Cohort 1a (Combo) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|---|---|
| Safety and Tolerability of EO4010 in Combination With Nivolumab and/or Bevacizumab | 6 | 0 | 0 | 0 | 0 | 6 | 0 |
Immunogenicity response of EO4010 (all peptides) for the three tests together: IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]. A patient is defined as positive if the result of one of the three tests (IFN-gamma ElISpot \[IVS\], IFN-gamma ElISpot \[NS\], multimer staining \[NS\]) shows a positive response
| Participants | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Percentage of Patients With Shown Immunogenicity Againts EO4010 (All Peptides) | 17 | 2 | 0 | 10 | 5 |
Defined as the percentage of patients who have a partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
| Participants | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Overall Response Rate | 1 | 0 | 0 | 1 | 0 |
Defined as the percentage of patients who have achieved complete response, partial response or stable disease following Response Evaluation Criteria in Solid Tumors criteria
| Participants | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Disease Control Rate | 6 | 0 | 0 | 3 | 3 |
Defined as the time interval from first study treatment administration to partial or complete response following Response Evaluation Criteria in Solid Tumors criteria
| months | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Time to Response | 10.5 (10.5 to 10.5) | — | — | 10.5 (10.5 to 10.5) | — |
Defined as the time interval from first study treatment administration to disease progression or death in patients who achieve complete or partial response following Response Evaluation Criteria in Solid Tumors criteria
| months | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Duration of Response | 8.7 (NA to NA) | — | — | 8.7 (NA to NA) | — |
Defined as the time interval from the date of first study treatment administration to the date of progression following Response Evaluation Criteria in Solid Tumors criteria
| months | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Progression Free Survival | 1.9 (1.8 to 2.2) | 1.8 (1.8 to NA) | — | 1.8 (1.8 to 2.2) | 2.4 (1.8 to NA) |
Defined as the time interval from the date of first study treatment administration to the date of death due to any cause. Patients alive will be censored at the date of the last documented follow-up
| months | Overall (All Cohorts) | Cohort 1a (Overall) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|
| Overall Survival to the Date of Death Due to Any Cause. Patients Alive Will be Censored at the Date of the Last Documented Follow-up | 11.4 (9.7 to NA) | NA (10.1 to NA) | — | 11.2 (4.7 to NA) | NA (9.7 to NA) |
Collected over 24 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Overall (All Cohorts) | 15/25 (60%) | 6/25 (24%) | 25/25 (100%) |
| Cohort 1a (Overall) | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 1a (Monotherapy) | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Cohort 1a (Combo) | 1/3 (33.3%) | 0/3 (0%) | 3/3 (100%) |
| Cohorts 1b-1c-1d | — | — | — |
| Cohort 2 | 12/17 (70.6%) | 6/17 (35.3%) | 17/17 (100%) |
| Cohort 3a | 2/5 (40%) | 0/5 (0%) | 5/5 (100%) |
| Event | Overall (All Cohorts) | Cohort 1a (Overall) | Cohort 1a (Monotherapy) | Cohort 1a (Combo) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|---|---|
| PyelonephritisInfections and infestations | 2/25 | 0/3 | 0/3 | 0/3 | — | 2/17 | 0/5 |
| Acute myocardial infarctionCardiac disorders | 1/25 | 0/3 | 0/3 | 0/3 | — | 1/17 | 0/5 |
| Gastrointestinal obstructionGastrointestinal disorders | 1/25 | 0/3 | 0/3 | 0/3 | — | 1/17 | 0/5 |
| Respiratory tract infectionInfections and infestations | 1/25 | 0/3 | 0/3 | 0/3 | — | 1/17 | 0/5 |
| Infusion related reactionInjury, poisoning and procedural complications | 1/25 | 0/3 | 0/3 | 0/3 | — | 1/17 | 0/5 |
| Acute kidney injuryRenal and urinary disorders | 1/25 | 0/3 | 0/3 | 0/3 | — | 1/17 | 0/5 |
| Event | Overall (All Cohorts) | Cohort 1a (Overall) | Cohort 1a (Monotherapy) | Cohort 1a (Combo) | Cohorts 1b-1c-1d | Cohort 2 | Cohort 3a |
|---|---|---|---|---|---|---|---|
| Injection site reactionGeneral disorders | 21/25 | 3/3 | 3/3 | 0/3 | — | 14/17 | 4/5 |
| AstheniaGeneral disorders | 8/25 | 1/3 | 0/3 | 1/3 | — | 3/17 | 4/5 |
| DiarrhoeaGastrointestinal disorders | 5/25 | 0/3 | 0/3 | 0/3 | — | 3/17 | 2/5 |
| AnaemiaBlood and lymphatic system disorders | 5/25 | 1/3 | 0/3 | 1/3 | — | 4/17 | 0/5 |
| LymphadenopathyBlood and lymphatic system disorders | 1/25 | 1/3 | 0/3 | 1/3 | — | 0/17 | 0/5 |
| HyperthyroidismEndocrine disorders | 2/25 | 1/3 | 0/3 | 1/3 | — | 1/17 | 0/5 |
| Tooth abscessInfections and infestations | 1/25 | 1/3 | 0/3 | 1/3 | — | 0/17 | 0/5 |
| Wrong product administeredInjury, poisoning and procedural complications | 1/25 | 1/3 | 0/3 | 1/3 | — | 0/17 | 0/5 |
| PolyarthritisMusculoskeletal and connective tissue disorders | 1/25 | 1/3 | 0/3 | 1/3 | — | 0/17 | 0/5 |
| NeuralgiaNervous system disorders | 1/25 | 1/3 | 0/3 | 1/3 | — | 0/17 | 0/5 |
The IDMC recommended to open recruitment of Cohort 2 utilizing the same dose level as in the safety lead-in, (300μg of each peptide, i.e. 1 mL of EO4010 in adjuvant) for Cohort 2. Therefore, Cohorts 1 b-c-d were not opened as per sponsor decision.
| Age, Continuous(years) | Cohort 1a | Cohort 2 | Cohort 3a | Cohorts 1b-c-d | Total |
|---|---|---|---|---|---|
| Median | 55 (45 to 56) | 61 (52 to 71) | 42 (40 to 67) | — | 57 (50 to 67) |
| Sex: Female, Male(Participants) | Cohort 1a | Cohort 2 | Cohort 3a | Cohorts 1b-c-d | Total |
|---|---|---|---|---|---|
| Female | 2 | 9 | 3 | — | 14 |
| Male | 1 | 8 | 2 | — | 11 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1a | Cohort 2 | Cohort 3a | Cohorts 1b-c-d | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 3 | 0 | — | 3 |
| Not Hispanic or Latino | 3 | 14 | 5 | — | 22 |
| Unknown or Not Reported | 0 | 0 | 0 | — | 0 |
| Region of Enrollment(participants) | Cohort 1a | Cohort 2 | Cohort 3a | Cohorts 1b-c-d | Total |
|---|---|---|---|---|---|
| United States | 0 | 2 | 0 | — | 2 |
| France | 3 | 10 | 2 | — | 15 |
| Spain | 0 | 5 | 3 | — | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2023 to primary completion in May 2025, 23 months.
Results were first posted in Oct 2026, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Enterome